Careers Contact Us

EN

CN

Core Biopharmaceutical Products

Core Biopharmaceutical Products

Gan & Lee Pharmaceuticals specializes in the treatment of diabetes mellitus,
and has built a complete biopharmaceutical product portfolio covering long-acting, rapid-acting, and premixed insulin analogs.

Overview of the Product

Committed to accompanying each patient to manage blood glucose more stably and safeguard long-term health

Medical Product Website Portal

The products fully cover the three functional insulin submarkets: long-acting, rapid-acting, and premixed.

Currently, Gan & Lee Pharmaceuticals has five insulin analog products: long-acting insulin glargine injection (Basalin®), rapid-acting insulin lispro injection (Prandilin®), insulin aspart injection (Rapilin®), premixed protamine zinc recombinant insulin lispro injection (25R) (Prandilin® 25), and insulin aspart 30 injection (Rapilin® 30), as well as one human insulin product: premixed protamine human insulin injection (30R) (Similin® 30).

Core Biopharmaceutical Products

Core Biopharmaceutical Products

The company has multiple insulin analog products, including long-acting insulin glargine injection (Basalin®), rapid-acting insulin lispro injection (Prandilin®), and insulin aspart injection (Rapilin®), among others, as well as a series of premixed insulin products. At the same time, the company is actively developing innovative biopharmaceuticals such as glucagon-like peptide-1 (GLP-1) receptor agonists, covering the full spectrum of diabetes mellitus.

Learn More
Core Chemical Drug Products

Core Chemical Drug Products

Gan & Lee Pharmaceuticals continues to invest in R&D in the field of chemical drugs and develops a pipeline of innovative chemical drugs focused on metabolic diseases and related therapeutic areas. Through a combination of independent R&D and collaborative development, the company continuously enriches its chemical drug product portfolio.

Learn More